GlassScriptPhysician profile
Erum Farooqi
NPI 1235391533
$4,319.83
in general payments reported to CMS, 2019-2025
35 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $201 · 2021: $265 · 2022: $639 · 2023: $1,122 · 2024: $996 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,846.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,127.09 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Shield Therapeutics INC | $447.51 | 2023-2025 | Accrufer |
| Lilly USA, LLC | $429.09 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $403.54 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $278.21 | 2019-2025 | Airsupra, Farxiga |
| W. L. Gore & Associates, INC. | $231.92 | 2019 | |
| Abbvie INC. | $209.79 | 2021-2025 | |
| Pfizer INC. | $152.07 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $123.98 | 2022-2024 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.54 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Glaxosmithkline, LLC. | $102.97 | 2021-2025 | Shingrix, Pediarix, Bexsero |
| Sanofi-Aventis U.S. LLC | $69.51 | 2019-2021 | |
| Corcept Therapeutics | $64.44 | 2020-2021 | |
| Amarin Pharma, INC. | $61.61 | 2020-2021 | |
| Vertex Pharmaceuticals Incorporated | $58.94 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.29 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $54.66 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $29.38 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $26.80 | 2025 | Rexulti |
| Omeza LLC | $24.69 | 2023 | |
| Eisai INC. | $24.05 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.14 | 2024 | |
| Axsome Therapeutics, INC. | $20.47 | 2025 | Auvelity |
| Radius Health, INC. | $19.06 | 2022 | |
| Astellas Pharma US INC | $18.99 | 2023 | Veozah |
| Amgen INC. | $18.62 | 2022 | |
| Sanofi Pasteur INC. | $17.42 | 2025 | |
| Esperion Therapeutics, INC. | $17.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.06 | 2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $15.82 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.18 | 2025 | Caplyta |
| Allergan, INC. | $13.93 | 2020 | |
| Genentech USA, INC. | $12.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.13 | 2021 | |
| Phathom Pharmaceuticals, INC. | $7.95 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erum Farooqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.